- Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension2007 | First Faculty of Medicine
- Ambrisentan in the treatment of pulmonary arterial hypertension2009 | First Faculty of Medicine
- Pulmonary arterial hypertension +22009 | First Faculty of Medicine
- Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)2020 | First Faculty of Medicine
- Ambrisentan, selective endothelin receptor ETa antagonist, in the treatment of pulmonary arterial hypertension2010 | First Faculty of Medicine
- SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension2017 | First Faculty of Medicine
- Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension2013 | First Faculty of Medicine
- Current pharmacotherapeutic options for systemic sclerosis2011 | Faculty of Medicine in Hradec Králové
- Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial2018 | First Faculty of Medicine
- Drug therapy of pulmonary arterial hypertension in 20142014 | First Faculty of Medicine
- Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension2022 | First Faculty of Medicine
- Medical treatment of pulmonary arterial hypertension2005 | First Faculty of Medicine
- Zarethan in the treatment of hypertension2008 | Third Faculty of Medicine
- Pulmonary arterial hypertension in systemic connective diseases +12008 | Faculty of Medicine in Hradec Králové
- Effect of Macitentan on Hospitalizations: Results From the SERAPH IN Trial2015 | First Faculty of Medicine
- Chronic thromboembolic pulmonary hypertension: role of medical therapy2013 | First Faculty of Medicine
- RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors2017 | First Faculty of Medicine
- Macitentan Improves Health- Related Quality of Life for Patients With Pulmonary Arterial Hypertension2017 | First Faculty of Medicine
- Current advances in the treatment of chronic pulmonary hypertension2023 | First Faculty of Medicine
- Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases Insights From Pulmonary Arterial Hypertension2019 | First Faculty of Medicine
- Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial2021 | First Faculty of Medicine